Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Forte Biosciences | 2025 | Post Ipo Equity | $75.0M | Sherman Oaks |
| Heartflow | 2025 | Convertible Note | $98.0M | Mountain View |
| Arbor Biotechnologies | 2025 | Series C | $73.9M | Cambridge |
| Curevo | 2025 | Series B | $110.0M | Bothell |
| Claris Biotherapeutics | 2025 | Debt Financing | $5.6M | Jersey City |
| Wallbox | 2025 | Post Ipo Equity | $15.0M | Barcelona |
| Aligos Therapeutics | 2025 | Post Ipo Equity | $105.0M | San Francisco |
| Ottimo Pharma | 2024 | Series A | $140.0M | Sandwich |
| New Amsterdam Pharma | 2024 | Post Ipo Equity | $452.6M | Naarden |
| Janux Therapeutics | 2024 | Post Ipo Equity | $350.0M | La Jolla |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 126 | Forte Biosciences | Post Ipo Equity | $75.0M | Sherman Oaks, United States |
| 127 | Heartflow | Convertible Note | $98.0M | Mountain View, United States |
| 128 | Arbor Biotechnologies | Series C | $73.9M | Cambridge, United States |
| 129 | Curevo | Series B | $110.0M | Bothell, United States |
| 130 | Claris Biotherapeutics | Debt Financing | $5.6M | Jersey City, United States |
| 131 | Wallbox | Post Ipo Equity | $15.0M | Barcelona, Spain |
| 132 | Aligos Therapeutics | Post Ipo Equity | $105.0M | San Francisco, United States |
| 133 | Ottimo Pharma | Series A | $140.0M | Sandwich, United Kingdom |
| 134 | New Amsterdam Pharma | Post Ipo Equity | $452.6M | Naarden, The Netherlands |
| 135 | Janux Therapeutics | Post Ipo Equity | $350.0M | La Jolla, United States |
Forte Biosciences is a biotechnology company that focuses on dermatology.
Heartflow is a medical technology company that provides various methods of diagnosis and treatment of cardiovascular disease.
Arbor Biotechnologies is a biotechnology company specializing in next-generation gene editing therapeutics to treat genetic diseases.
Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines for infectious diseases.
Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars.
Wallbox is a technology company that provides electric vehicle charging and energy management solutions.
Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities.
Ottimo Pharma develops innovative cancer therapies using PD1-VEGFR2 antibodies.
New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.
Janux Therapeutics develops immunotherapies that generates immune responses to prevent tumors and not affecting a patient’s healthy tissue.
35Pharma is a biopharmaceutical company that designs and develops innovative biologics for diseases of high unmet medical need.
Metsera is a clinical‐stage biotech firm developing oral & injectable hormone therapies to treat obesity & related metabolic diseases.
Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.
Alpha-9 Oncology is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies.
Aktis Oncology is a biotechnology company that designs and develops novel class radiopharmaceuticals.
Ventyx is a biopharmaceutical company focused on advancing oral therapies for patients living with autoimmune and inflammatory disorders.
Elektrofi develops hyper concentration microparticle technology for subcutaneous biologic medicine delivery.
Inspirato is a luxury travel and lifestyle subscription company.
Day One Biopharmaceuticals develops targeted therapies to treat people with life-threatening diseases.
Scorpion Therapeutics is a clinical-stage oncology company that specializes in precision medicine for cancer patients.
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
CARGO Therapeutics develops an adoptive cell therapy to benefit patients from potentially curative treatment options.
P3 Health Partners is a patient-centered, physician-led and population health-focused healthcare company.
Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras.
Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for treatment.
Janus Henderson Investors has invested in 175 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Janus Henderson Investors's top investment sectors include Biotechnology, Health Care, Pharmaceutical, Life Science, Medical. The firm invests across 30 different industry categories.
Among tracked funding rounds, New Amsterdam Pharma received $452.6M in a Post Ipo Equity round. Janus Henderson Investors's total known invested capital is $12.5B.
Janus Henderson Investors's average investment size is $129.0M across its portfolio of 175 companies.
Recent Janus Henderson Investors portfolio additions include Forte Biosciences, Heartflow, Arbor Biotechnologies, Curevo, Claris Biotherapeutics. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors